ポスター発表資料
Human Pharmacokinetics and NASH Development Strategy for PXL065 – Deuterium-Stabilized (R)-Pioglitazone
Sebastien Bolze, et al. — March 2021, NASH-TAG
Phase 1b Study of PXL065 (Deuterium-Stabilized R-Pioglitazone), a Novel NASH Candidate, Predicts 15 mg Equivalent to 45 mg Actos®
Sebastien Bolze, et al. — November 2020, AASLD (American Association for the Study of Liver Diseases)
PXL770, a Novel Direct AMP-activated Protein Kinase Activator Produces Greater Efficacy when Combined with Other Key Therapeutic Mechanisms Targeting NASH
Pierre-Axel Monternier, et al. — November 2020, AASLD (American Association for the Study of Liver Diseases)
PXL770, A New Direct AMP Kinase Activator and Potential NASH Therapeutic, Produces Anti-inflammatory Effects in Mouse Liver and Adipose Tissue and in Human Immune Cells
Pascale Gluais-Dagorn, et al. — November 2020, AASLD (American Association for the Study of Liver Diseases)
PXL770, a Novel Direct AMP-activated Protein Kinase Activator, Improves Hepatic Mitochondrial Function in a Rodent NASH Model
Pierre-Axel Monternier, et al. — November 2020, AASLD (American Association for the Study of Liver Diseases)
Long-term treatment with imeglimin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes (TIMES 2) (Phase 3)
J. Dubourg et al. — September 2020, EASD (European Association for the Study of Diabetes)
Efficacy And Safety Of Imeglimin In Combination With Insulin In Japanese Patients With Type 2 Diabetes: Results of TIMES 3 Trial (Phase 3)
J. Dubourg et al. — September 2020, EASD (European Association for the Study of Diabetes)
Chronic Treatment With The Direct AMP Kinase Activator PXL770 Improves Cardiac And Renal Function In Diabetes Related Cardiorenal Syndrome
Y. Stephan et al. — September 2020, EASD (European Association for the Study of Diabetes)
Phase 1 Study of PXL065 Confirms Dose-Proportionality & Stabilization of the Preferred Stereoisomer (R-Pioglitazone) for the Treatment of NASH
Bolze et al. — November 2019, AASLD (American Association for the Study of Liver Diseases), Boston, MA, USA
Safety, Tolerability & PK of PXL065*, the Stabilized R-Stereoisomer of Pioglitazone: A Mitochondrial Function Modulator for NASH without PPARγ Agonism & Related Side Effects
Vincent Jacques et al. — November 2018, AASLD (American Association for the Study of Liver Diseases), San Francisco, USA
PXL770, a New Direct AMP Kinase Activator, Acting on the Adipose Tissue and the Liver, Demonstrates Promising Effects for Treatment of Non-Alcoholic Steatohepatitis
Pascale Gluais-Dagorn et al. — November 2018, AASLD (American Association for the Study of Liver Diseases), San Francisco, USA
PXL770, a direct AMPK activator, shows favorable cardiac safety profile
Sophie Hallakou-Bozec et al. — October 2018, International Meeting on AMPK, Toronto, Canada
PXL770, a direct AMPK activator for the treatment of NASH, shows a favorable PK, tolerability and safety profile in humans
Sandrine Perrimond-Dauchy et al. — October 2018, International Meeting on AMPK, Toronto, Canada
Imeglimin Protects Ins-1 Cells And Human Islets Against High Glucose- And High Fructose-induced Cell Death By Inhibiting The Mitochondrial PTP Opening
Sandrine Lablanche et al. — June 2018, ADA (American Diabetes Association), Orlando, USA
PXL770, a new direct AMP Kinase activator, demonstrates promising effects for treatment of non-alcoholic steatohepatitis
Pascale Gluais-Dagorn et al. — February 2018, Global NASH Congress, London, UK
Imeglimin monotherapy in Japanese patients with type 2 diabetes: results from a randomised, 24-week, double-blind, placebo-controlled, phase IIb trial
J. Dubourg — September 2017, EASD (European Association for the Study of Diabetes), Lisbon, Portugal
Short- and long-term imeglimin treatment reduces metabolic syndrome-related diabetic cardiomyopathy
Marianne Lachaux et al. — August 2017, EASD (European Association for the Study of Diabetes), Barcelona, Spain
Imeglimin Opposes Development of Metabolic Syndrome Related Diabetic Cardiomyopathy
Marianne Lachaux et al. — June 2017, ADA (American Diabetes Association), San Diego, USA
Imeglimin Preserves β-cell Function and Mass in Male Zucker Diabetic Fatty Rats World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
Sophie Hallakou-Bozec et al. — December 2016, WCIRDC (World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease), Los Angeles, California, USA
Efficacy of DRX-065, the stabilized R-enantiomer of pioglitazone (pio), in choline-deficient (CD) and methionine/choline-deficient (MCD) diet mouse models of nonalcoholic steatohepatitis (NASH)
Sharon C. Cheetham et al. — November 2016, AASLD (American Association for the Study of Liver Diseases), Nottingham, UK
PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mouse model of obesity and diabetes EASD,
Sébastian Bolze et al. — September 2016, EASD (European Association for the Study of Diabetes), Munich, Germany
PXL770, a Novel Direct AMPK Activator, Inhibits Hepatic de novo Lipogenesis for the Treatment of Metabolic Disorders EASD
Sophie Hallakou-Bozec et al. — September 2016, EASD (European Association for the Study of Diabetes), Munich, Germany
Imeglimin Improves Vascular Dysfunction in Type 2 Diabetes Animal Models EASD
Fouqueray P et al. — September 2016, EASD (European Association for the Study of Diabetes), Munich, Germany
Imeglimin Improves Insulin Sensitivity in an Adult STZ Rat Model ADA
Sophie Hallakou-Bozec et al. — June 2016, ADA (American Diabetes Association), New Orleans, USA
Imeglimin Increases Insulin Secretion in Response to Glucose as a Unique Mechanism of Action Depending on NAD Synthesis ADA
Sophie Hallakou-Bozec et al. — June 2016, ADA (American Diabetes Association), New Orleans, USA
PXL770 Demonstrates Therapeutic Potential as a New Direct AMP Kinase Activator WCIRDC
Sophie Hallakou-Bozec et al. — November 2015, WCIRDC (World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease), Los Angeles, USA
Imeglimin, a New Oral Anti-Hyperglycemic Agent Controls Fasting and Post-Prandial Glucose through an Improvement in both Insulin Secretion and Insulin Sensitivity WCIRDC
Fouqueray P et al. — November 2015, WCIRDC (World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease), Los Angeles, USA
Dose Ranging-Study to Determine the Optimum Dose for Imeglimin, a Novel Treatment for Type 2 Diabetes.
Fouqueray P et al. — June 2015, ADA (American Diabetes Association), Boston, USA
Imeglimin decreases hepatic glucose production through a unique mitochondrial mechanism of action.
Vial G et al. — June 2014, ADA (American Diabetes Association), San Francisco, USA
Imeglimin: A new antidiabetic agent that provides added benefit to DPP-4 inhibitor therapy.
Fouqueray P et al. — June 2013, ADA (American Diabetes Association), Chicago, USA
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy
Fouqueray P et al. — June 2012, ADA (American Diabetes Association), Philadelphia, USA
The effects of the antidiabetic Imeglimin in hyperglycemic mice with septic shock.
Wagner F et al. — March 2012, ISICEM (International Symposium on Intensive), Brussels, Belgium
Imeglimin, a novel glimin oral anti-diabetic, exhibits good glycemic control in type 2 diabetic patients.
Pirags V et al. — September 2010, EASD (European Association for the Study of Diabetes), Stockholm, Sweden